Research analysts at HC Wainwright started coverage on shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in a note issued to investors on Sunday. The firm set a “buy” rating and a $5.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 66.67% from the stock’s previous close.

Several other equities analysts have also recently commented on the stock. ValuEngine cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald restated an “overweight” rating on shares of BioDelivery Sciences International in a research report on Sunday, August 20th. Piper Jaffray Companies set a $4.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Wednesday, August 9th. Janney Montgomery Scott boosted their target price on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $4.21.

Shares of BioDelivery Sciences International (NASDAQ BDSI) opened at 3.00 on Friday. The company has a market capitalization of $166.43 million, a PE ratio of 107.14 and a beta of 1.04. The firm’s 50-day moving average is $3.19 and its 200 day moving average is $2.42. BioDelivery Sciences International has a 52 week low of $1.50 and a 52 week high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.04. The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. BioDelivery Sciences International’s quarterly revenue was up 74.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. On average, analysts anticipate that BioDelivery Sciences International will post $0.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/10/biodelivery-sciences-international-inc-bdsi-now-covered-by-hc-wainwright.html.

Several institutional investors have recently made changes to their positions in the stock. Stonepine Capital Management LLC grew its holdings in shares of BioDelivery Sciences International by 22.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after purchasing an additional 632,853 shares during the last quarter. EAM Investors LLC bought a new stake in shares of BioDelivery Sciences International during the 2nd quarter valued at approximately $1,348,000. Advisor Group Inc. grew its holdings in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 13,341 shares during the last quarter. Northern Trust Corp grew its holdings in shares of BioDelivery Sciences International by 0.9% during the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after purchasing an additional 1,203 shares during the last quarter. Finally, GSA Capital Partners LLP grew its holdings in shares of BioDelivery Sciences International by 10.1% during the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 44,700 shares during the last quarter. 41.44% of the stock is currently owned by institutional investors.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.